Recruiting studies: Metastatic Melanoma In The Central Nervous System

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
Phase 2 · 1 location(s) · Sheba Medical Center · NCT05909618 Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to
Phase 3 · 270 location(s) · NRG Oncology · NCT06500455 Melanoma Metastasized to the Brain and Steroids
Phase 2 · 3 location(s) · Inge Marie Svane · NCT03563729 Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to
Phase 1/Phase 2 · 1 location(s) · Kari Kendra · NCT05588453 A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced So
Phase 1 · 83 location(s) · Pfizer · NCT05538130 Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05026983 Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04771520 A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V60
Phase 2 · 331 location(s) · SWOG Cancer Research Network · NCT04511013

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.